Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.08 per share and revenue of $136.32 million for the quarter.
Amicus Therapeutics Trading Up 2.1 %
Shares of NASDAQ:FOLD traded up $0.15 during mid-day trading on Friday, hitting $7.35. The stock had a trading volume of 3,683,896 shares, compared to its average volume of 2,622,764. The company's 50 day moving average is $8.16 and its 200-day moving average is $9.40. Amicus Therapeutics has a 12-month low of $6.20 and a 12-month high of $12.65. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a market cap of $2.26 billion, a PE ratio of -40.83, a P/E/G ratio of 1.51 and a beta of 0.79.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on FOLD. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Wells Fargo & Company dropped their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $16.75.
View Our Latest Report on Amicus Therapeutics
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Further Reading
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
